| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/INFDIS/165.6.987 |
| P698 | PubMed publication ID | 1583345 |
| P2093 | author name string | J. D. Meyers | |
| B. Osborne | |||
| C. A. Gleaves | |||
| A. Benson | |||
| G. A. Storch | |||
| R. C. Hackman | |||
| R. D. Harrington | |||
| T. M. Hooton | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bone marrow | Q546523 |
| disease outbreak | Q3241045 | ||
| P304 | page(s) | 987-993 | |
| P577 | publication date | 1992-06-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | An outbreak of respiratory syncytial virus in a bone marrow transplant center | |
| P478 | volume | 165 |
| Q91777235 | A clinical approach to respiratory disease in patients with hematological malignancy, with a focus on respiratory infection |
| Q33950824 | A comparison of cytomegalovirus and community respiratory viruses in immunocompromised patients |
| Q59360858 | A multifaceted approach to RSV vaccination |
| Q91633846 | A phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory tract infection in hematopoietic-cell transplant recipients |
| Q45734694 | A prospective surveillance of nosocomial respiratory syncytial virus infection in a hematology ward: a single-center experience in Japan |
| Q37627348 | A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology. |
| Q34484085 | Agents that increase AAM differentiation blunt RSV-mediated lung pathology |
| Q34465570 | Altered pathogenesis of severe pneumovirus infection in response to combined antiviral and specific immunomodulatory agents |
| Q45722741 | An outbreak of respiratory syncytial virus infection in a bone marrow transplant unit: effect on engraftment and outcome of pneumonia without specific antiviral treatment |
| Q33956935 | Antiviral Chinese medicinal herbs against respiratory syncytial virus |
| Q93238882 | Antiviral agents against respiratory viruses |
| Q62079263 | Benign outcome of RSV infection in children with cancer |
| Q45784353 | Can respiratory syncytial virus and influenza A be distinguished clinically in institutionalized older persons? |
| Q37687412 | Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation |
| Q60936344 | Clinical Features, Severity, and Incidence of RSV Illness During 12 Consecutive Seasons in a Community Cohort of Adults ≥60 Years Old |
| Q47746602 | Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin |
| Q35122262 | Common community respiratory viruses in patients with cancer: more than just "common colds". |
| Q33950850 | Community respiratory viral infections in the immunocompromised host: past, present, and future directions |
| Q34330068 | Community respiratory virus infections following lung transplantation |
| Q33950804 | Community respiratory virus infections in immunocompromised patients with cancer |
| Q90067548 | Community-Acquired Respiratory Viruses in Transplant Patients: Diversity, Impact, Unmet Clinical Needs |
| Q80906323 | Community-acquired respiratory viruses |
| Q39973043 | Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic stem cell transplant recipients |
| Q44903223 | Current research on respiratory viral infections: Fifth International Symposium. |
| Q35887641 | Detection of influenza vaccine effectiveness among nursery school children: Lesson from a season with cocirculating respiratory syncytial virus |
| Q40443431 | Determination of phosphorylated residues from human respiratory syncytial virus P protein that are dynamically dephosphorylated by cellular phosphatases: a possible role for serine 54. |
| Q33976579 | Efficacy of RD3-0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice. |
| Q45722195 | Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates |
| Q26344301 | Guideline for infection control in healthcare personnel, 1998 |
| Q28388806 | Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective |
| Q39612863 | High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention |
| Q34213683 | Hospital infection control in hematopoietic stem cell transplant recipients |
| Q51849785 | Hospital outbreak of human respiratory syncytial virus (HRSV) illness in immunocompromised hospitalized children during summer. |
| Q36717602 | Human antibodies from combinatorial libraries. |
| Q30946151 | Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity |
| Q33746756 | Human rhinovirus detection in the lower respiratory tract of hematopoietic cell transplant recipients: association with mortality |
| Q34307704 | Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. |
| Q45728526 | Identification of a novel human leucocyte antigen-A*01-restricted cytotoxic T-lymphocyte epitope in the respiratory syncytial virus fusion protein |
| Q43746561 | Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines |
| Q30308165 | Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. |
| Q42267417 | Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. |
| Q33950831 | Infection control of nosocomial respiratory viral disease in the immunocompromised host |
| Q39820778 | Infection in the bone marrow transplant recipient and role of the microbiology laboratory in clinical transplantation. |
| Q43779240 | Infection prevention and control in residential facilities for pediatric patients and their families |
| Q34305094 | Infections following hematopoietic stem cell transplantation |
| Q40639264 | Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. |
| Q47623866 | Infections in adults undergoing unrelated donor bone marrow transplantation |
| Q33769714 | Infections in recipients of blood and marrow transplantation |
| Q37150434 | Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. |
| Q36933029 | Isolation and characterization of a chimpanzee monoclonal antibody to the G glycoprotein of human respiratory syncytial virus |
| Q36169360 | Isolation in the allogeneic transplant environment: how protective is it? |
| Q39199992 | Low mortality rates related to respiratory virus infections after bone marrow transplantation |
| Q36506275 | Molecular characterization of a respiratory syncytial virus outbreak in a hematology unit in Heidelberg, Germany |
| Q34191801 | Molecular epidemiology of respiratory syncytial virus |
| Q35913866 | Molecular investigations of an outbreak of parainfluenza virus type 3 and respiratory syncytial virus infections in a hematology unit |
| Q34249859 | New insights for development of a safe and protective RSV vaccine |
| Q37501564 | Nosocomial infections in patients with cancer. |
| Q34033632 | Nosocomial respiratory syncytial virus infections: the "Cold War" has not ended |
| Q33975722 | Nosocomial spread of viral disease |
| Q42279293 | Oral ribavirin for treatment of respiratory syncitial virus and parainfluenza 3 virus infections post allogeneic haematopoietic stem cell transplantation |
| Q45370052 | Oral ribavirin therapy for lower respiratory tract infection of respiratory syncytial virus complicating bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation |
| Q40535767 | Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmes. |
| Q43407951 | Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model |
| Q44512888 | Parainfluenza virus infection in adult bone marrow transplant recipients |
| Q35129182 | Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation |
| Q41927260 | Post-transplant Viral Respiratory Infections in the Older Patient: Epidemiology, Diagnosis, and Management. |
| Q33950838 | Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients |
| Q34722706 | Prevention and treatment of viral infections in stem cell transplant recipients |
| Q41676840 | Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery |
| Q51718949 | Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab). |
| Q45491056 | Primary infection of mice with high titer inoculum respiratory syncytial virus: characterization and response to antiviral therapy |
| Q37991125 | Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients |
| Q36322131 | Prospects of antiviral and anti-inflammatory therapy for respiratory syncytial virus infection |
| Q35740698 | Pulmonary complications of solid organ and hematopoietic stem cell transplantation |
| Q38905025 | Pulmonary infiltrates in the cancer patient. New approaches to an old problem |
| Q50551742 | RSV prevention and treatment in pediatric lung transplant patients: a survey of current practices among the International Pediatric Lung Transplant Collaborative. |
| Q36534733 | Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults. |
| Q31521336 | Recent progress in antiviral chemotherapy for respiratory syncytial virus infections |
| Q33645414 | Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. |
| Q42855455 | Replication and clearance of respiratory syncytial virus: apoptosis is an important pathway of virus clearance after experimental infection with bovine respiratory syncytial virus |
| Q35526996 | Respiratory Syncytial Virus Prophylaxis in Special Populations: Is it Something Worth Considering in Cystic Fibrosis and Immunosuppression? |
| Q38202574 | Respiratory infections |
| Q40836386 | Respiratory syncytial virus (RSV) disease and prospects for its control |
| Q33812405 | Respiratory syncytial virus genetic and antigenic diversity |
| Q45744471 | Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience |
| Q45733327 | Respiratory syncytial virus infection following hematopoietic stem cell transplantation |
| Q33961877 | Respiratory syncytial virus infection in adults |
| Q30351086 | Respiratory syncytial virus infection in elderly adults. |
| Q40662545 | Respiratory syncytial virus infection in the elderly |
| Q34299730 | Respiratory syncytial virus infection in the late bone marrow transplant period: report of three cases and review |
| Q45378669 | Respiratory syncytial virus infection outbreak among pediatric patients with oncologic diseases and/or BMT. |
| Q45070426 | Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins |
| Q40560679 | Respiratory syncytial virus infections in human beings and in cattle |
| Q33410539 | Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes |
| Q45766266 | Respiratory syncytial virus pneumonia in an AIDS patient |
| Q36155097 | Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome |
| Q44923546 | Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin |
| Q45790395 | Respiratory syncytial virus, a rare cause of severe pneumonia following bone marrow transplantation |
| Q44828154 | Respiratory syncytial virus-related pneumonia after stem cell transplantation successfully treated with palivizumab and steroid therapy |
| Q41535011 | Respiratory syncytial virus: not just for kids |
| Q33950796 | Respiratory viral infections in immunocompetent and immunocompromised persons |
| Q43601975 | Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit |
| Q33834945 | Respiratory viral infections in the elderly |
| Q35989482 | Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection |
| Q45741859 | Respiratory virus infections after marrow transplant: the Fred Hutchinson Cancer Research Center experience |
| Q45735386 | Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation |
| Q45741856 | Respiratory virus infections in bone marrow transplant recipients: the European perspective |
| Q45735858 | Respiratory virus infections in pediatric hematopoietic stem cell transplantation |
| Q24655957 | Respiratory viruses other than influenza virus: impact and therapeutic advances |
| Q42256954 | Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit |
| Q33961412 | Risk factors for respiratory failure associated with respiratory syncytial virus infection in adults |
| Q26768419 | Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review |
| Q39872216 | Role of T-lymphocyte subsets in recovery from respiratory syncytial virus infection in calves |
| Q34466061 | Role of plasma membrane lipid microdomains in respiratory syncytial virus filament formation |
| Q44148387 | Severe respiratory syncytial virus pneumonia complicating fludarabine and cyclophosphamide treatment of chronic lymphocytic leukemia |
| Q40774513 | Special considerations for the patient undergoing allogeneic or autologous bone marrow transplantation. |
| Q42262215 | Successful systemic high-dose ribavirin treatment of respiratory syncytial virus-induced infections occurring pre-engraftment in allogeneic hematopoietic stem cell transplant recipients |
| Q73497825 | Summary of the II international consensus symposium on combined antiviral therapy and implications for future therapies |
| Q40480527 | The Laboratory Diagnosis of Pneumonia: The Role of the Community Hospital Pathologist |
| Q37266577 | The challenge of respiratory virus infections in hematopoietic cell transplant recipients |
| Q37284406 | Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation |
| Q90745119 | Transmission and Control of Respiratory Viral Infections in the Healthcare Setting |
| Q33689234 | Treatment of RSV pneumonia in adults--evidence of ribavirin effectiveness? |
| Q36961083 | Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. |
| Q39118448 | Viral Pneumonia in Patients with Hematologic Malignancy or Hematopoietic Stem Cell Transplantation |
| Q37824989 | Viral infections in immunocompromised patients |
| Q40594928 | Viral infections in severely immunocompromised cancer patients |
| Q37788451 | Viral pneumonias in immunocompromised adult hosts |
| Q33869751 | Viral pneumonias. Epidemic respiratory viruses |
| Q36864610 | Viral respiratory tract infections in transplant patients: epidemiology, recognition and management |
| Q37619850 | Virus infection facilitates the development of severe pneumonia in transplant patients with hematologic malignancies |
| Q92061400 | Virus respiratorio sincitial, metapneumovirus y virus parainfluenza humanos: cuadro clínico y fisiopatología |
| Q50587371 | [Respiratory syncytial virus pneumonia in four immunocompromised adults]. |
Search more.